Literature DB >> 22576240

Predicting the effects of amino acid replacements in peptide hormones on their binding affinities for class B GPCRs and application to the design of secretin receptor antagonists.

Jerez A Te1, Maoqing Dong, Laurence J Miller, Andrew J Bordner.   

Abstract

Computational prediction of the effects of residue changes on peptide-protein binding affinities, followed by experimental testing of the top predicted binders, is an efficient strategy for the rational structure-based design of peptide inhibitors. In this study we apply this approach to the discovery of competitive antagonists for the secretin receptor, the prototypical member of class B G protein-coupled receptors (GPCRs). Proteins in this family are involved in peptide hormone-stimulated signaling and are implicated in several human diseases, making them potential therapeutic targets. We first validated our computational method by predicting changes in the binding affinities of several peptides to their cognate class B GPCRs due to alanine replacement and compared the results with previously published experimental values. Overall, the results showed a significant correlation between the predicted and experimental ΔΔG values. Next, we identified candidate inhibitors by applying this method to a homology model of the secretin receptor bound to an N-terminal truncated secretin peptide. Predictions were made for single residue replacements to each of the other nineteen naturally occurring amino acids at peptide residues within the segment binding the receptor N-terminal domain. Amino acid replacements predicted to most enhance receptor binding were then experimentally tested by competition-binding assays. We found two residue changes that improved binding affinities by almost one log unit. Furthermore, a peptide combining both of these favorable modifications resulted in an almost two log unit improvement in binding affinity, demonstrating the approximately additive effect of these changes on binding. In order to further investigate possible physical effects of these residue changes on receptor binding affinity, molecular dynamics simulations were performed on representatives of the successful peptide analogues (namely A17I, G25R, and A17I/G25R) in bound and unbound forms. These simulations suggested that a combination of the α-helical propensity of the unbound peptide and specific interactions between the peptide and the receptor extracellular domain contribute to their higher binding affinities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576240      PMCID: PMC3565385          DOI: 10.1007/s10822-012-9574-x

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  36 in total

1.  A simple physical model for binding energy hot spots in protein-protein complexes.

Authors:  Tanja Kortemme; David Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

2.  Large-scale prediction of protein geometry and stability changes for arbitrary single point mutations.

Authors:  A J Bordner; R A Abagyan
Journal:  Proteins       Date:  2004-11-01

3.  Computational alanine scanning of protein-protein interfaces.

Authors:  Tanja Kortemme; David E Kim; David Baker
Journal:  Sci STKE       Date:  2004-02-03

4.  Interaction of secretin5-27 and its analogues with hormone receptors on pancreatic acini.

Authors:  J D Gardner; A J Rottman; S Natarajan; M Bodanszky
Journal:  Biochim Biophys Acta       Date:  1979-04-03

5.  Synthesis and some pharmacological properties of the 23-peptide 15-lysine-secretin-(5--27). Special role of the residue in position 15 in biological activity of the vasoactive intestinal polypeptide.

Authors:  M Bodansky; S Natarajan; J D Gardner; G M Makhlouf; S I Said
Journal:  J Med Chem       Date:  1978-11       Impact factor: 7.446

6.  Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.

Authors:  P Nicole; L Lins; C Rouyer-Fessard; C Drouot; P Fulcrand; A Thomas; A Couvineau; J Martinez; R Brasseur; M Laburthe
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

7.  Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.

Authors:  Hisato Igarashi; Tetsuhide Ito; Tapas K Pradhan; Samuel A Mantey; Wei Hou; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

8.  Lactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist.

Authors:  Maoqing Dong; Jerez A Te; Xiequn Xu; Jinhui Wang; Delia I Pinon; Laura Storjohann; Andrew J Bordner; Laurence J Miller
Journal:  Biochemistry       Date:  2011-08-30       Impact factor: 3.162

9.  Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.

Authors:  S Runge; B S Wulff; K Madsen; H Bräuner-Osborne; L B Knudsen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

10.  Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig. Structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3':5'-monophosphate.

Authors:  P Robberecht; T P Conlon; J D Gardner
Journal:  J Biol Chem       Date:  1976-08-10       Impact factor: 5.157

View more
  2 in total

1.  Rational development of a high-affinity secretin receptor antagonist.

Authors:  Maoqing Dong; Kaleeckal G Harikumar; Sweta R Raval; Juliana E Milburn; Carolyn Clark; Rafael Alcala-Torano; Juan C Mobarec; Christopher A Reynolds; Giovanna Ghirlanda; Arthur Christopoulos; Denise Wootten; Patrick M Sexton; Laurence J Miller
Journal:  Biochem Pharmacol       Date:  2020-03-23       Impact factor: 5.858

2.  Secretin Receptor as a Target in Gastrointestinal Cancer: Expression Analysis and Ligand Development.

Authors:  Anja Klussmeier; Stefan Aurich; Lars Niederstadt; Bertram Wiedenmann; Carsten Grötzinger
Journal:  Biomedicines       Date:  2022-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.